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Abstract 
Background: Malignant Mesothelioma (MM) is a highly aggressive tumor with poor prognosis. Multimodal treat-
ments and novel molecular targeted therapies against MM are in high demand in order treat this disease effectively. 
We have developed a humanized monoclonal antibody YS110 against CD26 expressed in 85 % of MM cases. CD26 is 
thought to be involved in tumor growth and invasion by interacting with collagen and fibronectin, or affecting signal 
transduction processes.
Methods: We evaluated the direct anti-tumor effect of YS110 against MM cell lines, NCI-H2452 and JMN, and investi-
gated its effects on cell cycle and on the cell cycle regulator molecules. In addition, we investigated synergistic effects 
of YS110 and anti-tumor agent pemetrexed (PMX) against MM cell line both in vitro and in vivo.
Results: YS110 suppressed the proliferation of NCI-H2452 cells by approximately 20 % in 48 h. Based on cell cycle 
analysis, percentage of cells in G2/M phase increased 8.0 % on the average after YS110 treatment; in addition, cell 
cycle regulator p21 cip/waf1 was increased and cyclin B1 was decreased after YS110 treatment. Inhibitory phos-
phorylation of both cdc2 (Tyr15) and cdc25C (Ser216) were elevated. Furthermore, activating phosphorylation of 
p38 MAPK (Thr180/Tyr182) and ERK1/2 (Thr202/Tyr204) were augmented at 24 h after YS110 treatment. PMX rapidly 
induced CD26 expression on cell surface and the treatment with both YS110 and PMX inhibited in vivo tumor growth 
accompanied by a synergistic reduction in the MIB-1 index.
Conclusion: This is a first report of a novel anti-proliferative mechanism of the humanized anti-CD26 monoclonal 
antibody YS110, which resulted in G2/M cell cycle delay through regulation of quantity and activity of various cell 
cycle regulating molecules.
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Background
Malignant mesothelioma (MM) is an aggressive can-
cer of the pleura, peritoneal cavity, pericardium, and 
scrotum and has a poor prognosis. MM is associated 
with occupational exposure to asbestos and, despite 
legislation introduced by many industrialized countries, 
the incidence is not expected to peak until 2020 due to 
the long latency between initial exposure and disease 
expression [1]. As single modality approach to treatment 
has failed to extend survival, multimodal treatment and 
novel molecular targeted therapies are highly sought 
after. Although extrapleural pneumonectomy (EPP) is 
a preferred treatment option, median survival among 
patients receiving EPP alone is less than 10  months [2]. 
EPP followed by high-dose radiation therapy (RT) has 
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been shown to prolong median survival to 33.8  months 
in patients with Stage 1 and Stage 2 MM but survival 
remained 10  months in patients with Stage 3 and Stage 
4 MM [2]. A Phase 3 trial showed that combination of 
pemetrexed and cisplatin improved survival over cispl-
atin alone for inoperable patients [3]. According to recent 
multicenter trials of trimodality treatment that con-
sisted of neoadjuvant chemotherapy (cisplatin and pem-
etrexed), EPP, and adjuvant RT led in the USA [2] and 
Europe [4], median survival of patients who completed 
the therapy was 29.1  months compared to 18.4  months 
in controls. Since the trimodality approach seems to be 
limited and because not all patient can tolerate aggressive 
therapies, novel molecular targeted therapies are highly 
desirable. To date, a number of molecular targeted agents 
have been evaluated in MM. While tyrosine kinase inhib-
itors against epidermal growth factor receptor (EGFR) 
and platelet-derived growth factor receptor (PDGFR) did 
not show clinically significant effects, histone deacetylase 
inhibitor (HDACI) and anti-angiogenic agents showed 
some clinical benefits and are undergoing Phase 3 trials 
[5]; however, none of these agents have been incorpo-
rated into clinical practice and efforts must continue in 
the area of both clinical research and search for novel tar-
get molecules.
CD26 is an 110 kD glycoprotein anchored in the cellu-
lar membrane with dipeptidyl peptidase IV activity. CD26 
is also known as a co-stimulatory molecule of the T lym-
phocyte. CD26 binds to caveolin-1 on antigen-presenting 
cells and the interaction triggers signal transduction pro-
cess leading to T cell proliferation and cytokine produc-
tion [6]. Several recent studies have shown that CD26 is 
highly expressed in several malignancies, including MM, 
lung adenocarcinoma, hepatocellular carcinoma, prostate 
cancer, and thyroid cancer [7]. CD26 expression evalu-
ated by immunohistochemistry was positive in 85  % of 
tested MM cases [8, 9]. Moreover, CD26 is thought to 
be involved in tumor growth and invasion through its 
interaction with collagen and fibronectin or by regulating 
activity of chemotactic peptides through its DPPIV activ-
ity. Furthermore, CD26 has been reported to be involved 
in signal transduction processes, including the p38 MAPK 
pathway. Though the mechanisms of action of CD26 have 
not been clarified, its enzymatic activity does not appear 
essential for its role in signal transduction process [10]. 
Considering its high rate of overexpression in MM and 
suspected function in tumor progression, we have devel-
oped a humanized an anti-CD26 antibody, designated 
YS110, as a targeted therapy against CD26-positive malig-
nancies, including MM. We have previously reported the 
anti-tumor effects of YS110 against MM cells [11]. In 
addition to the anti-tumor effect via antibody-depend-
ent-cell-mediated-cytotoxicity, YS110 showed direct 
anti-tumor effect via p27kip1 accumulation [11]; however, 
the molecular mechanism of direct anti-tumor effect of 
YS110 against MM cell lines remains unknown.
The molecular mechanisms underlying the direct anti-
tumor effect of several monoclonal antibodies have been 
investigated; for example, the anti-HER-2 antibody (Tras-
tuzumab) and anti-EGFR antibody (Cetuximab) result in 
G1/S cell cycle arrest by upregulating the CDK inhibi-
tor p27kip1 via multiple signaling pathways [12, 13]. The 
anti-CD20 antibody (rituximab) can induce cell death of 
malignant B cell lymphoma cells in vitro via inhibition of 
the p38 MAPK, ERK1/2, and AKT anti-apoptotic sur-
vival pathways [14]. Most therapeutic antibodies against 
cancers that affect the cell cycle, including antibodies 
mentioned above, result in G1/S arrest. So far, only one 
anti-cancer antibody, the anti-human type 1 insulin-like 
growth factor receptor (IGF-IR) antibody A12 against 
androgen-independent prostate cancer cell line LuCaP 
35  V, has been reported to cause G2/M cell cycle delay 
although its molecular mechanism is not yet understood 
[15].
In this study, we focused on evaluating the direct 
in vitro effect of the humanized anti-CD26 monoclonal 
antibody YS110 against the MM cell line NCI-H2452 
and investigated its effect on the cell cycle and on cell 
cycle-regulating molecules. YS110 inhibited growth 
of YS110 with G2/M cell cycle arrest and altered the 
expression or phosphorylation state of cell cycle mol-
ecules. Furthermore, pemetrexed (PMX), a standard 
reagent against mesothelioma, rapidly induced CD26 
expression on the cell surface and treatment with both 
YS110 and PMX inhibited in  vivo tumor growth in a 
synergistic manner. This is the first report describing 
a novel anti-proliferative mechanism of the human-
ized anit-CD26 monoclonal antibody YS110, which 
resulted in G2/M cell cycle delay, through regulation 
of quantity and activity of various cell cycle-regulating 
molecules.
Results
YS110 inhibits mesothelioma cell proliferation
YS110 inhibits proliferation of the mesothelioma cell 
line NCI-H2452 in a concentration-dependent manner 
(Fig.  1). Maximum of growth inhibition was 18.3  % at 
250 μg/mL of YS110. Based on this result, we used YS110 
at 2 μg/mL, which showed 11.2 % of growth inhibition, in 
the following experiments.
YS110 induced G2/M cell cycle delay in mesothelioma cells
To investigate the mechanism responsible for the 
growth inhibition caused by YS110, cell-cycle distri-
bution was determined by flow cytometry analysis. At 
24  h after YS110 treatment, the percentage of cells in 
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the G2/M phase increased compared to the control. 
The representative experiment is shown (Fig.  2a). On 
the average of ten experiments, the percentage of G2/M 
phase cells were significantly increased after YS110 
treatment (p < 0.05) (Fig. 2b). This cell cycle delay may 
be compatible with repression of cell proliferation. Fur-
thermore, in another CD26 positive MM cell line NCI-
H28, the percentage of cells in G2/M phase increased 
by 5 % on the average after YS110 treatment though its 
significance could not be proved statistically (data not 
shown).
YS110 alters cell cycle regulators
We investigated the alterations caused by YS110 treat-
ment in the quantity and activation state of cell cycle 
regulators responsible for G2/M transition. At 24  h 
after YS110 treatment, the cell cycle regulator p21 
increased while the positive regulatory subunit cyclin 
B1 decreased. Inhibitory phosphorylation of cdc2 on 
Tyr15 and inhibitory phosphorylation of cdc25C on 
Ser216, an upstream inhibitory regulator of cdc2, was 
elevated (Fig. 3a). Cdc25C phosphorylated on Ser216 is 
known to be sequestrated into cytoplasm and refrained 
from contact with cdc2 [16]. After YS110 treatment 
for 24 h, cytoplasmic whole cdc25C was elevated while 
nuclear whole cdc25C was decreased, as confirmed by 
densitometry analysis (Fig.  3b). At 6  h and 12  h after 
YS110 treatment, the amount of phosphorylated cdc2 
and phosphorylated cdc25C were varied among experi-
ments despite consistent increase at 24 h. No significant 
change in cdc25A and cdc25B was observed (data not 
shown).
YS110 elevates activating phosphorylation of p38 MAPK 
and ERK1/2
In order to determine the upstream regulator of cdc25C 
phosphorylation caused by YS110 treatment, expres-
sion and activation status of several molecules known to 
regulate cell cycle through cdc25C phosphorylation were 
examined. Activating phosphorylation of p38 MAPK 
(Thr180/Tyr182) and ERK1/2 (Thr202/Tyr204) were 
elevated 24 h after YS110 treatment (Fig. 4a). No signifi-
cant change in chk1, chk2, or c-TAK1 was observed (data 
not shown). While the p38 inhibitor SB203580 failed to 
block G2/M arrest caused by YS110 (data not shown), the 
MEK1/2 inhibitor U0126 blocked G2/M arrest caused by 
YS110 according to cell cycle analysis using flowcytom-
etry (Fig. 4b).
Pemetrexed (PMX) increased CD26 expression in 
mesothelioma cells in vitro
CD26 expression on the cell surface of JMN cells 
increased 15 % from 6 to 6.5 % 24 h after treatment with 
10 μM of PMX based on flowcytometry analysis (Fig. 5a). 
In order to confirm the augmented expression of CD26 
in JMN cells, Western blot analysis was performed. CD26 
protein expression was rapidly induced in whole cell 
lysates by treatment with 10 μM of PMX at 1 h after PMX 
treatment; most augmentation of CD26 expression at 6 h 
and then this augmented expression continued to 24  h 
after PMX treatment (Fig.  5b). In order to examine the 
altered expression of CD26 in NCI-H2452 cells, Western 
blot analysis was performed. CD26 protein expression in 
NCI-H2452 cells was also rapidly induced in whole cell 
lysates by treatment with 10 μM of PMX at 1 h after PMX 
treatment; most augmentation of CD26 expression at 6 h 
and then this augmented expression continued to 24  h 
after PMX treatment (Fig. 5b).
Effective inhibition of in vivo mesothelioma cell growth by 
combined treatment with both YS110 and PMX
Combination effects of YS110 and PMX were examined 
using xenograft models with JMN cells transplanted into 
NOG mice subcutaneously. Mice were then monitored 
for the development and progression of tumors and the 
tumor size was determined by caliper measurement. 
Tumor size in mice treated with both YS110 and PMX 
was smaller than mice treated with only YS110 or PMX 
(data not shown). The weight of tumors with YS110 treat-
ment was insignificantly reduced (Fig.  6A). PMX treat-
ment induced a significant reduction in tumor weight 
(p  <  0.05); the combination of YS110 and PMX treat-
ment synergistically reduced tumor weight compared 




























Fig. 1 YS110 inhibits NCI-H2452 cell proliferation. WST-1 assay 
revealed inhibition of NCI-H2452 cell proliferation with YS110 treat-
ment in a concentration-dependent manner up to 18.6 %. The experi-
ment was performed using 96 multi-well plates
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Combination effects of tumor growth in  vivo were 
examined by measuring the MIB-1 index histologically. 
The MIB-1 index was significantly decreased in tumors 
after YS110 or PMX single treatment compared with 
controls (p  <  0.05; Fig.  6B, C). Combinatory treatment 
with YS110 and PMX significantly reduced the MIB-1 
index compared to single treatment (p < 0.05; Fig. 6B, C).
Histology of the tumor derived from JMN cells in the 
xenograft model is shown in Fig. 6C. Sarcomatous meso-
thelioma is shown in HE staining (Fig. 6C-a) and stained 
with anti-CD26 polyclonal antibody (R&D) (Fig.  6C-b). 
The MIB-1 index was measured by immunohistochem-
istry using the anti-Ki-67 (MIB-1) monoclonal anti-
body. Staining of Ki-67 antigens in nucleus was shown 
in tumors treated with control IgG (Fig.  6C-c), YS110 
(Fig.  6C-d), and both YS110 and PMX (Fig.  6C-e). The 
number of Ki-67 positive nuclei was decreased after 
combined treatment of YS110 and PMX and the necrotic 


















































Fig. 2 YS110 induces G2/M cell cycle delay in NCI-H2452 cells. a 
Flowcytometry analysis using propidium iodide staining revealed that 
the percentage of G2/M phase cells increased while the percentage 
of G1 phase cells was reduced in NCI-H2452 cells treated 24 h with 
2 μg/mL of YS110. A representative experiment is shown. b The aver-
age percentage of G2/M phase cells in NCI-H2452 cells treated 24 h 































Fig. 3 YS110 alters expressions and phosphorylation of cell cycle 
regulators. a At 24 h after treatment with 2 μg/mL of YS110, p21 
protein expression increased while cyclinB1 protein expression 
decreased. Inhibitory phosphorylation of cdc2 Tyr15 and cdc25C 
Ser216 were elevated while there was no significant change in whole 
cdc2 and cdc25C protein. β-actin was used as an internal control. 
b Alteration in subcellular distribution of whole cdc25C by YS110 
treatment is shown. At 24 h after treatment with 2 μg/mL of YS110, 
nuclear cdc25C protein decreased while cytoplasmic cdc25C protein 
increased. LaminA/C was used as a nuclear marker and Na–K ATPase 
was used as a cytoplasmic marker. The bar graph demonstrates the 
densitometric analysis of a Western blot of whole cdc25C. Results are 
normalized by the densitometry of control cells. All experiments were 
performed in triplicate and a representative experiment is shown
Page 5 of 10Hayashi et al. Cancer Cell Int  (2016) 16:35 
Discussion
Novel molecular targeted therapies are in high demand 
since the aggressive trimodality approach against MM 
has been proved to be limited. We developed a human-
ized monoclonal antibody against CD26, designated as 
YS110, a molecular targeted therapy against MM [11]. 
We expected YS110 to cause ADCC to eliminate CD26 
positive MM cells. In addition to the ADCC effect, YS110 
demonstrated direct anti-proliferative effects in  vitro 
against CD26-positive MM cell lines. We proposed that 
investigation into the molecular mechanisms of the 
direct anti-proliferative effect against MM cells would 
be beneficial for both understanding anti-tumor effect of 
YS110, as well as uncover the underlying mechanism its 
proliferation and progression. Although the direct anti-
proliferative effect of YS110 is limited to a repression rate 
of approximately 20 % in vitro, the molecular mechanism 
was associated with the proliferative signal transduction 
system and cell cycle. Cell cycle analysis revealed that 
YS110 caused significant delay of the G2/M transition. To 
our knowledge, only one anti-cancer MoAb, anti-IGF-IR 








































Fig. 4 YS110 augments phosphorylation of p38MAPK and ERK1/2. 
a Activating phosohorylation of p38 (Thr180/Tyr182) and ERK1/2 
(Thr202/Tyr204) were elevated by 24 h after treatment with YS110 
while no substantial changes of whole p38 and ERK1/2 protein were 
observed. β-actin was used as an internal control. b G2/M arrest 
caused by YS110 treatment was reversed by ERK1/2 activation inhibi-
tor U0126 (10 μM). A proportion (43.15 %) of G2/M was elevated in 
cells with YS110 treatment compared with in cells without YS110 
(control, 37.05 %) and the proportion of G2/M decreased in cells with 
both YS110 and U0126 treatment (35.06 %). All experiments were 

















Fig. 5 Pemetrexed (PMX) increased CD26 expression in vitro. a Based 
on flowcytometry analysis, cell surface CD26 expression on JMN 
cells increased 6-24 h after treatment with 10 μM of PMX. b Based 
on Western blot analysis, the expression of CD26 protein was rapidly 
induced in whole cell lysates by treatment with 10 μM of PMX at 
1–24 h. GAPDH was used as an internal control. All experiments were 
performed in triplicate and a representative experiment is shown
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cancer cell line LaCaP 35 V, has been reported to result 
in G2/M delay although its molecular mechanism is not 
yet understood [15]. Therefore, we are the first to report 
results on the molecular mechanisms underlying G2/M 
delay from a cancer targeted-antibody. In order to eluci-
date the mechanism of G2/M delay mediated by YS110, 
we analyzed the quantities and phosphorylation status 
of G2/M regulators using Western blot analysis. At 24 h 
after treatment with YS110, inhibitory phosphorylation 
of cdc2 and its upstream regulator cdc25C were elevated. 
Phosphorylation of Cdc25C on Ser216 is sequestrated 
into the cytoplasm and therefore restrained from con-
tact with nuclear cdc2. Increased levels of cytoplasmic 
whole cdc25 protein and decreased levels of nuclear 
whole cdc25C protein at 24 h occurred after YS110 treat-
ment, confirming sequestration. Western blot analysis 
also revealed an increased amount of cell cycle inhibi-
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Fig. 6 Effective inhibition of mesothelioma cell growth in vivo. A Combination effects of YS110 and PMX were examined using xenograft models 
with JMN cells transplantation subcutaneously. The weight of tumors treated with YS110 was insignificantly reduced but PMX treatment induced 
a significantly reduced tumor weight (*p < 0.05). A combination of YS110 and PMX treatment reduced tumor weight compared with the weight 
of tumors with YS110 single treatment and PMX single treatment synergistically (**p < 0.05). B Combination effects of tumor growth in vivo were 
examined using a measurement of MIB-1 index histologically. MIB-1 index was significantly reduced with YS110 or PMX single treatment compared 
with control IgG treatment (*p < 0.05). The MIB-1 index after combinatory treatment with YS110 and PMX was significantly reduced compared 
with YS110 or PMX single treatment (**p < 0.05). C Sarcomatous mesothelioma is shown in HE staining (a) and stained with anti-CD26 polyclonal 
antibody (R&D) (b) MIB-1 index was measured by immunohistochemistry using the anti-Ki-67 monoclonal antibody (DAKO, clone MIB-1). Staining of 
Ki-67 antigens in nucleus is seen in tumors treated with control IgG (c), YS110 (d), and both YS110 and PMX (e). The number of Ki-67 positive nucleus 
was reduced after combinatory treatment of YS110 and PMX and the necrotic area is indicated by an asterisk (e)
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G2/M progression at 24 h after YS110 treatment. These 
alterations may be compatible with the retarded G2/M 
transition.
To determine the upstream regulator of the altered 
cdc25C phosphorylation state caused by YS110, we inves-
tigated several molecules known to regulate cdc25C. 24 h 
after YS110 treatment, activated phosphorylation levels 
of p38 MAPK (Thr180/Thy182) and ERK 1/2 (Thr202/
Tyr204) were elevated. Inhibitor assays indicated that 
YS110 treatment activated the ERK signal pathway, but 
not the p38MAPK pathway, which induced G2/M delay.
MAPK activation results in many different biologi-
cal responses, including proliferation, differentiation, 
and cell death. Although ERK1/2 activation is associated 
with cell survival and proliferation, a number of studies 
have shown that activation of ERK1/2 can mediate cell 
cycle arrest and cell death depending on the stimuli and 
cell types involved [17]. A number of anti-cancer rea-
gents and an anti-cancer antibodies have been reported 
to induce G2/M cell cycle arrest and/or apoptosis medi-
ated by ERK1/2 activation [18, 19]. These reagents, like 
YS110, cause G2/M cell cycle delay by inhibiting phos-
phorylation of cdc2 and cdc25C and by activating phos-
phorylation of ERK1/2. The G2/M delay caused by these 
drugs is antagonized by MEK inhibitors. Among mono-
clonal antibodies that have been investigated for their 
anti-cancer characteristics, the anti-CD40 antibody has 
been reported to cause apoptosis of diffuse large B-cell 
lymphoma cell lines with ERK1/2 activation through 
CD40 signaling [20]. In these reported cases, as well as 
our findings of YS110-CD26 interaction, the mechanisms 
underlying G2/M delay or apoptosis through ERK1/2 
activation is still unknown. As for G1/S cell cycle regula-
tion, a report has indicated that HER2 signaling related 
to trastuzumab treatment had effects on CDC25A pro-
tein stability [21]. The involvement of cell cycle regulators 
on the effect of anti-tumor antibodies should be further 
investigated.
Previously, we reported that YS110 induces intra-
nuclear transportation of CD26. When bound to YS110, 
CD26 is translocated to the nucleus via caveolin-depend-
ent endocytosis. This translocation suppresses transcrip-
tion of the POLR2A gene, which encodes a large subunit 
of RNA polymerase, in MM cell lines [22, 23]. The rela-
tionship between POLR2A suppression and G2/M cell 
cycle delay also requires further investigation.
The NCI-H2452 cell line is derived from the epithelioid 
type of MM and its growth rate is lower than the sarco-
matoid type of MM, the JMN cell line [24]. Profiles of 
cell cycling for synchronization assay in S-phase by thy-
midine block are available for NCI-H2452 cells but not 
for JMN cells. NCI-H2452 cells have no tumorigenicity in 
immunodeficient mice but JMN cells form subcutaneous 
tumors or diffuse and spread into the thorax [11, 22, 
and 23]; therefore, after YS110 treatment, we examined 
the in vitro cell cycle using NCI-H2452 cells and in the 
in vivo xenograft model using JMN cells.
Pemetrexed (PMX) induced augmented CD26 expres-
sion in both NCI-H2452 cells and JMN cells rapidly 
(Fig. 5b); this induction of cell surface CD26 on MM cells 
may be useful for anti-CD26 MoAb therapy against MM. 
The combination of YS110 and PMX therapy against xen-
ografted MM tumors was applied using JMN cell trans-
planted immunodeficient mice. As a result, anti-tumor 
effects were significantly shown in xenografted tumors 
with YS110 and PMX combined treatment compared to 
tumors with single treatment of YS110 or PMX, which 
was accompanied by a significantly reduced MIB-1 index. 
The combined treatment with YS110 and PMX showed a 
tendency to retard both G1/S and G2/M transition; how-
ever, significant differences of G1/S or G2/M proportion 
were not seen between YS110 plus PMX treatment and 
YS110 or PMX single treatment (data not shown).
There have been many anti-cancer monoclonal anti-
bodies (MoAbs) developed and their anti-cancer mech-
anisms are highly variable. Investigations into each 
molecular mechanism of an anti-cancer MoAb are sig-
nificant because it is valuable for the optimization of 
antibody therapies against cancer and contributes to 
elucidating the mechanisms of oncogenesis and cancer 
proliferation. This is the first report of a novel anti-pro-
liferative mechanism of a humanized anti-CD26 mono-
clonal antibody YS110 causing G2/M cell cycle delay 
through ERK1/2 phosphorylation and identifying PMX 
as a CD26 inducer.
Conclusions
Humanized anti-CD26 monoclonal antibody YS110 sup-
pressed proliferation of CD26 positive MM cell lines 
through a novel mechanism causing G2/M cell cycle 
delay through ERK1/2 phosphorylation. Anti-tumor 
agent PMX was identified as a CD26 inducer.
Methods
Reagents and antibodies
The humanized anti-CD26 antibody YS110 was con-
structed from the anti-CD26 mouse monoclonal anti-
body 14D10 coding sequence as previously described 
[11] and normal human IgG1 (Southern Biotech, Bir-
mingham, AL) was used as a control. Rabbit monoclonal 
antibody to cyclinB1, p21cip/waf1, cdc2, phospho-cdc2 
(Tyr15), cdc25c, phospho-cdc25c (Ser216), Erk1/2, 
phospho-Erk1/2(Thr202/Tyr204), p38MAPK, and phos-
phor-p38MAPK (Thr180/Tyr182) were from Cell Sign-
aling Technology Inc. (Danvers, MA) and the mouse 
monoclonal antibody against β-actin or Glyceraldehyde 
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3-phosphate dehydrogenase (GAPDH) was from DAKO 
(Glostrup, Denmark). The goat anti-CD26 polyclonal 
antibody and MEK 1/2 inhibitor U0126 was from Cell 
Signaling Technology Inc. (Danvers, MA).
Cell culture
NCI-H2452, NCI-H28 and JMN, CD26-positive cell 
lines established from malignant mesothelioma, were 
kind gifts from Dr. Chikao Morimoto (Departement of 
Therapy Development and Innovation for Immune Dis-
orders and Cancers, Juntendo University). Both cell lines 
were grown in RPMI medium (Sigma-Aldrich, Tokyo, 
Japan) supplemented with 10  % heat-inactivated fetal 
bovine serum (FBS), ABPC (100 unit/mL), Streptomycin 
(100 μg/mL), and 5 % CO2 at 37 °C.
Cell proliferation assay
The effect of YS110 on the proliferation of NCI-H2452 
cells was measured using a colorimetric cell prolifera-
tion kit WST-1 (Roche Diagnostics, Tokyo, Japan) based 
on the colorimetric detection of a formazan salt. In brief, 
5  ×  103 NCI-H2452 cells were seeded in RPMI1640 
medium supplemented with 10 % heat inactivated FBS on 
96-well plate with or without 2 μg/mL YS110. After 48 h 
of incubation at 37  °C in 5 % CO2, a reading at 450 nm 
was carried out according to the manufacturer’s instruc-
tions. Background absorbance of each sample at 630 nm 
was subtracted from the readings at 450 nm. The experi-
ment was performed in triplicate and a representative 
experiment is shown.
Cell cycle assay and flowcytometry
For the cell cycle study, NCI-H2452 and NCI-H28 cells 
were synchronized in the S-phase by a repeated thymi-
dine block. In brief, 5  ×  105 cells seeded in RPMI1640 
medium supplemented with 10  % heat inactivated fetal 
bovine serum on 10 cm culture dishes were treated with 
0.56 mM thymidine for 18 h, released for 10 h by three 
washes, and then treated again with 0.56 mM thymidine 
for 15  h. Synchronized cells were then returned to thy-
midine free medium with or without 2 μg/mL YS110 and 
incubated for 24 h. Cell cycle profiles were performed by 
flowcytometry using a procedure for propidium iodide 
staining of nuclei. Acquisition was performed using an 
EPICS XL/XL-MCL version 3.0 (Beckman Coulter, Brea, 
CA, USA) and data were analyzed using Flowjo software 
(TreeStar, Ashland, OR, USA). The experiment was per-
formed in triplicate and a representative experiment is 
shown.
Western blotting
For total cell lysate preparation, NCI-H2452 cells or JMN 
cells cultured with or without 2  μg/mL YS110 for 24  h 
were lysed at 4 °C by lysis buffer with phosphatase inhibi-
tors (50 mM Tris–HCl, 150 mM NaCl, 1 % NP-40, 0.25 % 
deoxycholate, 500 μM NaVO3, 50 mM NaF). For the prep-
aration of nuclear and cytoplasmic extracts, NCI-H2452 
cells were processed using NE-PER Nuclear and Cytoplas-
mic Extraction Reagents (Thermo scientific, Waltham, 
LA) according to the manufacturer’s instruction. For 
Western blot analyses, 30 μg of each cell lysate was sep-
arated on an SDS–polyacrylamide gel and transferred 
to a PVDF membrane Hybond-P (GE Healthcare, Little 
Chalfont, UK). The membranes were blocked in blocking 
buffer [5 % dry milk and 0.2 % Tween 20 in Tris buffered 
saline (TBS)] for 2 h at room temperature, and incubated 
with the primary antibodies in antibody dilution buffer 
(5 % bovine serum albumin, 0.2 % Tween 20 in TBS) over-
night at 4 °C. Dilutions of primary antibodies were 1:200, 
except anti p21cip/waf1 antibody, which was diluted at 
1:100. After three washes, the blots were incubated with 
secondary antibodies (goat anti-rabbit polyclonal anti-
body and rabbit anti-mouse polyclonal antibody) diluted 
1:1000 with dilution buffer for 1  h at room temperature 
and developed using the ECL Western Blotting Detection 
Reagents (GE Healthcare, Little Chalfont, UK). Quan-
tification of relative band densities was performed using 
standard densitometry scanning techniques using Image-
Quant 350 and ImageQuant TL software (GE Healthcare, 
Little Chalfont, UK). All the experiments performed in 
triplicate and a representative experiment is shown.
Xenograft model using human mesothelioma cell lines
NOD/Shi-scid, IL-2 receptor gamma null (NOG) mice 
were obtained from the Central Institute for Experimen-
tal Animals. JMN cells (1  ×  106) were implanted sub-
cutaneously in the back flank of NOG mice. Mice were 
injected intratumorally with control human IgG1 (n = 3) 
or YS110 (n = 3) at doses of 5 mg/kg body weight. JMN 
cells expressing CD26 were inoculated into the thoracic 
cavities of NOG mice. Thereafter, mice were intraperi-
toneally injected with control human IgG1 (n  =  3) or 
YS110 (5  μg per injection; n  =  3), and/or pemetrexed 
(PMX, purchased from Eli Lilly; 100 mg/kg body weight) 
commencing on the day of cancer cell injection. Each 
antibody was administered three times per week. Mice 
were then monitored for the development and progres-
sion of tumors. Tumor weight was measured by scale. All 
experiments were approved by the Animal Care and Use 
Committee of Keio University and were performed in 
accordance with the institute guidelines.
Histology and immunohistochemistry
Tumor tissues were fixed in 10 % neutral buffered forma-
lin, embedded in paraffin, and sectioned at a thickness of 
5 μm. Sections were paraffin depleted and rehydrated in a 
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graded series of ethanol solutions. For histology, sections 
were stained with hematoxylin and eosin. For immuno-
histochemistry, sections were washed with PBS, sub-
jected to antigen retrieval by heating at 100 °C in 0.01 M 
sodium citrate (pH 6.0) for 10  min, then treated with 
3 % H2O2, before incubation with the following primary 
antibodies: goat anti-CD26 pAb (AF1180, R&D Systems, 
Minneapolis, MN) (1:100) and mouse anti-Ki-67 mAb 
(MIB-1, DAKO Japan) (1:100). Immune complexes were 
detected by using an ImmPRESS REAGENT KIT (Vector 
Laboratories, Burlingame, CA) with 3, 3′-diaminobenzi-
dine, and sections were counterstained with hematoxylin
Statistical analyses
Statistical analyses were assessed using SPSS version 17.0 
(SPSS Inc., Chicago, IL). The p value, from which statisti-
cal significance was assumed, was set to p < 0.05.
Abbreviations
MM: malignant mesothelioma; PMX: pemetrexed; NOG mouse: NOD/Shi-scid, 
IL-2 receptor gamma null mouse.
Authors’ contributions
MH and TY designed and performed the research; HN and CM provided 
reagents and cells and examined protein expressions; HM, MS and TY analyzed 
the data; MH and TY wrote the manuscript. All authors read and approved the 
final manuscript.
Author details
1 Department of Pathology, Keio University School of Medicine, 35 Shina-
nomachi, Tokyo, Shinjuku-ku 160-8582, Japan. 2 Department of Pediatrics, Keio 
University School of Medicine, 35 Shinanomachi, Tokyo, Shinjuku-ku 160-8582, 
Japan. 3 Laboratory of Nuclear Transport Dynamics, National Insititute of Bio-
medical Innovation, 7-6-8 Saito-Asagi, Ibaraki City, Osaka Prefecture 567-0085, 
Japan. 4 Department of Therapy Development and Innovation for Immune 
Disorders and Cancers, Juntendo University, 2-1-2 Hongo, Tokyo, Bunkyo-ku 
113-8421, Japan. 5 Department of Pathology, Saitama Medical University, 38 
Morohongo, Saitama, Moroyama-machi 350-0495, Japan. 
Acknowledgements
We thank H. Suzuki for technical assistance and A. Sato and K. Tsutsumi for 
animal care and support of tumorigenicity assay.
Competing interests
YS110 was provided by Y’s therapeutics. TY and CM are possessing non-listed 
stock of Y’s therapeutics. MH and HN are paid by the consignment study cost 
of Y’s therapeutics. TY and CM are advisers for Kissei Pharmaceutical Co., Ltd, 
which carried out the Phase I clinical trial for YS110 against CD26 positive 
cancers. HM, KY, and MS have no competing interests.
Ethical approval
All animal experiments were approved by the Animal Care and Use Commit-
tee of Keio University and were performed in accordance with the institute 
guidelines.
Funding
This study was supported by the Program for Promotion of Fundamental 
Studies in Health Sciences of the National Institute of Biomedical Innovation 
(07–17 to TY and CM), a Grant-in-Aid for Scientific Research (B) (23390086 and 
16H04714 to TY and 22790355 to MH) and Global COE Program “Education 
and Research Center for Stem Cell Medicine” (to KY) from the Ministry of 
Education, Culture, Sports, Science and Technology of Japan, and a Grant-in-
Aid for Drug Design Biomarker Research (H24-B10-003 to TY and CM) from the 
Ministry of Health, Labor and Welfare and a Grant-in-Aid for Industrial Accident 
Clinical Research (H27-150401-01 to TY and CM) from the Ministry of Health, 
Labor and Welfare.
Received: 23 December 2015   Accepted: 24 April 2016
References
 1. Sugarbaker DJ. Multimodality management of malignant pleural meso-
thelioma: introduction. Semin Thorac Cardiovasc Surg. 2009;21:95–6.
 2. Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, 
Flores R, Friedberg JS, Pisters K, Monberg M, Obasaju CK, Vogelzang 
NJ. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin 
followed by extrapleural pneumonectomy and radiation for malignant 
pleural mesothelioma. J Clin Oncol. 2009;27:3007–13.
 3. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, 
Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase 
III study of pemetrexed in combination with cisplatin versus cisplatin 
alone in patients with malignant pleural mesothelioma. J Clin Oncol. 
2003;21:2636–44.
 4. Van Schil PE, Baas P, Gaafar R, Maat AP, Van de Pol M, Hasan B, Klomp HM, 
Abdelrahman AM, Welch J, van Meerbeeck JP. Trimodality therapy for 
malignant pleural mesothelioma: results from an EORTC phase II multi-
centre trial. Eur Respir J. 2010;36:1362–9.
 5. Greillier L, Marco S, Barlesi F. Targeted therapies in malignant pleu-
ral mesothelioma: a review of clinical studies. Anticancer Drugs. 
2011;22:199–205.
 6. Ohnuma K, Uchiyama M, Yamochi T, Nishibashi K, Hosono O, Takahashi 
N, Kina S, Tanaka H, Lin X, Dang NH, Morimoto C. Caveolin-1 triggers 
T-cell activation via CD26 in association with CARMA1. J Biol Chem. 
2007;282:10117–31.
 7. Bauvois B. Transmembrane proteases in cell growth and invasion: new 
contributors to angiogenesis? Oncogene. 2004;23:317–29.
 8. Aoe K, Amatya VJ, Fujimoto N, Ohnuma K, Hosono O, Hiraki A, Fujii M, 
Yamada T, Dang NH, Takeshima Y, Inai K, Kishimoto T, Morimoto C. CD26 
overexpression is associated with prolonged survival and enhanced 
chemosensitivity in malignant pleural mesothelioma. Clin Cancer Res. 
2012;18:1447–56.
 9. Amatya VJ, Takeshima Y, Kushitani K, Yamada T, Morimoto C, Inai K. Over-
expression of CD26/DPPIV in mesothelioma tissue and mesothelioma cell 
lines. Oncol Rep. 2011;26:1369–75.
 10. Antczak C, De Meester I, Bauvois B. Ectopeptidases in pathophysiology. 
Bio Essays. 2001;23:251–60.
 11. Inamoto T, Yamada T, Ohnuma K, Kina S, Takahashi N, Yamochi T, Inamoto 
S, Katsuoka Y, Hosono O, Tanaka H, Dang NH, Morimoto C. Humanized 
anti-CD26 monoclonal antibody as a treatment for malignant mesothe-
lioma tumors. Clin Cancer Res. 2007;13:4191–200.
 12. Le X-F, Pruefer F, Bast RC. HER2-targeting antibodies modulate the cyclin-
dependent kinase inhibitor p27Kip1 via multiple signaling pathways. Cell 
Cycle. 2005;4:87–95.
 13. Vincenzi B, Schiavon G, Silletta M, Santini D, Tonini G. The biological prop-
erties of cetuximab. Crit Rev Oncol Hematol. 2008;68:93–106.
 14. Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 
2010;47:115–23.
 15. Wu JD, Odman A, Higgins LM, Haugk K, Vessella R, Ludwig DL, Plymate 
SR. In vivo effects of the human type I insulin-like growth factor receptor 
antibody A12 on androgen-dependent and androgen-independent 
xenograft human prostate tumors. Clin Cancer Res. 2005;11:3065–74.
 16. Takizawa CG, Morgan DO. Control of mitosis by changes in the sub-
cellular location of cyclin-B1-Cdk1 and Cdc25C. Curr Opin Cell Biol. 
2000;12:658–65.
 17. Mebratu Y, Tesfaigzi Y. How ERK1/2 activation controls cell prolifera-
tion and cell death: is subcellular localization the answer? Cell Cycle. 
2009;8:1168–75.
 18. Zhang Z, Miao L, Lv C, Sun H, Wei S, Wang B, Huang C, Jiao B. Wentilac-
tone B induces G2/M phase arrest and apoptosis via the Ras/Raf/MAPK 
signaling pathway in human hepatoma SMMC-7721 cells. Cell Death Dis. 
2013;4:e657.
Page 10 of 10Hayashi et al. Cancer Cell Int  (2016) 16:35 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 19. Chuang M-J, Wu S-T, Tang S-H, Lai X-M, Lai H-C, Hsu K-H, Sun K-H, Sun 
G-H, Chang S-Y, Yu D-S, Hsiao P-W, Huang S-M, Cha T-L. The HDAC 
inhibitor LBH589 induces ERK-dependent prometaphase arrest in 
prostate cancer via HDAC6 inactivation and down-regulation. PLoS One. 
2013;8:e73401.
 20. Hollmann CA, Owens T, Nalbantoglu J, Hudson TJ, Sladek R. Constitutive 
activation of extracellular signal-regulated kinase predisposes diffuse 
large B-cell lymphoma cell lines to CD40-mediated cell death. Cancer 
Res. 2006;66:3550–7.
 21. Brunetto E, Ferrara AM, Rampoldi F, Talarico A, Cin ED, Grassini G, Spagnu-
olo L, Sassi I, Ferro A, Cuorvo LV, Barbareschi M, Piccinin S, Maestro R, 
Pecciarini L, Doglioni C, Cangi MG. CDC25A protein stability represents 
a previously unrecognized target of HER2 signaling in human breast 
cancer: implication for a potential clinical relevance in trastuzumab treat-
ment. Neoplasia. 2013;15:579–90.
 22. Yamada K, Hayashi M, Du W, Ohnuma K, Sakamoto M, Morimoto C, 
Yamada T. Localization of CD26/DPPIV in nucleus and its nuclear trans-
location enhanced by anti-CD26 monoclonal antibody with anti-tumor 
effect. Cancer Cell Int. 2009;9:17.
 23. Yamada K, Hayashi M, Madokoro H, Nishida H, Du W, Ohnuma K, Saka-
moto M, Morimoto C, Yamada T. Nuclear localization of CD26 induced 
by a humanized monoclonal antibody inhibits tumor cell growth by 
modulating of POLR2A transcription. PLoS ONE. 2013;8:e62304.
 24. Penno MB, Askin FB, Ma H, Carbone M, Vargas MP, Pass HI. High CD44 
expression on human mesotheliomas mediates association with hyaluro-
nan. Cancer J Sci Am. 1995;1:196–203.
